1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Prophylaxis: new trials by email Literature Review of Prophylaxis trials Research Report on Prophylaxis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) Islatravir, Placebo to FTC/TDF, FTC/TDF - HIV-I, Human Immunodeficiency Virus Type 1 | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 730 | 2021-02-24 | 2026-02-04 |
Acquired Immunodeficiency Syndrome (1)
Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1) · Sexually Transmitted Diseases, Viral (1) · Slow Virus Diseases (1) · Urogenital Diseases (1) · Virus Diseases (1)
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · islatravir (1)
South Africa (1) · Uganda (1) · United States (1)